EMILIO
ESTEBAN GONZALEZ
Profesor Titular de Universidad
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (25)
2023
-
Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3492-3500
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
2021
2020
-
ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148
-
Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)
BJU International, Vol. 126, Núm. 5, pp. 559-567
2019
-
Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease
Advances in Therapy, Vol. 36, Núm. 6, pp. 1497-1508
2018
-
Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286
2017
-
Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer
European Urology Focus, Vol. 3, Núm. 2-3, pp. 280-286
-
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Scientific Reports, Vol. 7
-
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421
-
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment
Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190
2016
-
Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations
Targeted Oncology, Vol. 11, Núm. 2, pp. 129-141
-
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
BMC Cancer, Vol. 16, Núm. 1
2015
2014
2013
-
Dolor como factor predictor de depresión en el paciente oncológico: estudio de casos y controles. Estudio D-PRESS
Revista de la Sociedad Espanola del Dolor, Vol. 20, Núm. 3, pp. 113-121
-
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
Annals of Oncology, Vol. 24, Núm. 9, pp. 2409-2414
-
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572
2011
-
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study
The Lancet Oncology, Vol. 12, Núm. 12, pp. 1143-1150
2010
-
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: Focus on special populations
Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1